Cefixime is an antibiotic in a class of drugs called cephalosporins. Cefixime fights bacteria in the body. Cefixime stops the bacteria from making their protein cell wall, so the bacteria die. Cefixime is used to treat gram negative bacteria. Cefixime fights bacteria in the body. Cefixime is used to treat many different types of bacterial infections such as bronchitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infection
Cefixime is a third-generation cephalosporin available in an oral formulation. In general, third-generation cephalosporins are more active against gram-negative species than are the earlier generations of cephalosporins. Like ceftriaxone and cefotaxime, cefixime has enhanced antibacterial activity and increased stability against many of the beta-lactamases. Cefixime is commonly used in the treatment of otitis media, respiratory tract infections, and urinary tract infections caused by susceptible organisms. Cefixime is one of the only CDC-recommended oral antimicrobial agents to which Neisseria gonorrhoeae has not developed significant resistance.
Cefixime inhibits the third and final stage of bacterial cell wall synthesis by preferentially binding to specific penicillin-binding proteins (PBPs) that are located inside the bacterial cell wall. Penicillin-binding proteins are responsible for several steps in the synthesis of the cell wall and are found in quantities of several hundred to several thousand molecules per bacterial cell. Penicillin-binding proteins vary among different bacterial species. Thus, the intrinsic activity of cefixime as well as the other cephalosporins and penicillins against a particular organism depends on its ability to gain access to and bind with the necessary PBP. Like all beta-lactam antibiotics, cefixime's ability to interfere with PBP-mediated cell wall synthesis ultimately leads to cell lysis. Lysis is mediated by bacterial cell wall autolytic enzymes (i.e., autolysins). The relationship between PBPs and autolysins is unclear, but it is possible that the beta-lactam antibiotic interferes with an autolysin inhibitor. In general, third-generation cephalosporins are more active against gram-negative species than are the earlier generations of cephalosporins. They are less active, however, against the gram-positive species than are their first-generation counterparts. The gram-positive coverage of cefixime is limited to group A streptococci and S. pneumoniae. Staphylococci, including S. aureus, are generally resistant to cefixime due to cefixime's low affinity to the PBPs of these organisms. The activity of cefixime against gram-negative organisms E. coli, Klebsiella, P. mirabilis, and S. marcescens is greater than that of other oral cephalosporins. Cefixime also displays enhanced antibacterial activity against non-beta-lactamase- and beta-lactamase-producing H. influenzae, N. gonorrhoeae, and Moraxella (Branhamella) catarrhalis due to the increased stability against many of the beta-lactamases.
Cefixime is used to treat many different types of bacterial infections such as bronchitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections. Cefixime may also be used for purposes other than those listed in this medication guide.
Molecular Formula: C16H21N5O8S2
Molecular Weight: 507.50
CAS No.: 79350-37-1